Breast Cancer | Disease Landscape and Forecast | G7 | 2021
Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are creating new dynamics in the treatment of metastatic HR-positive/HER2-negative disease. Meanwhile, novel HER2-targeted agents, label expansions, and biosimilar entries—all of which will lead to changes in treatment guidelines—will have an impact on sales of current drugs for HER2-positive breast cancer. Furthermore, the approval of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna), immune checkpoint inhibitors (Roche / Genentech / Chugai’s Tecentriq and Merck & Co.’s Keytruda), PI3K inhibitors (Novartis’s Piqray), HER2-targeted agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), and TROP2-targeted agents (Gilead’s Trodelvy), as well as the anticipated entry of other agents from these drug classes, will diversify treatment options, especially for triple-negative breast cancer.
QUESTIONS ANSWERED
- What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Keytruda, Piqray, Enhertu, and Tukysa, on the various subpopulations of breast cancer?
- What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
- What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
CONTENT HIGHLIGHTS
- Geographies: United States, EU5, Japan.
- Primary research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.
- Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.
- Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2030, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations.
- Emerging therapies: Phase III/PR: 18 drugs; coverage of select Phase I and II products.
